Viewing Study NCT07033494


Ignite Creation Date: 2025-12-25 @ 1:45 AM
Ignite Modification Date: 2025-12-27 @ 10:09 AM
Study NCT ID: NCT07033494
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2025-06-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Overview

Official Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease
Status: RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.

The goals of the study are to learn:

* If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.
* About the safety of MK-2214 and if people tolerate it
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
MK-2214-004 OTHER MSD View
2024-519190-19-00 REGISTRY EU CT View
U1111-1314-8296 REGISTRY UTN View
jRCT2031250299 REGISTRY Japan Registry of Clinical Trial (jRCT) View